Axelar is developing anti-cancer treatments that target the insulin-like growth factor-1 receptor signaling pathway.

The company’s lead drug candidate, AXL1717, is the first small molecule in clinical development that interferes with IGF-1 receptor signaling while having no observable effect on signaling from the almost identical insulin receptor.

Building on extraordinary efficacy results in animal studies and a successful Phase I/II program, Axelar has now completed a randomized, controlled, multicenter, multinational Phase II study on non-small cell lung cancer.

Axelar aims to partner with a pharmaceutical company to complete the clinical program and bring a product to market.